

Cellular Recognition of *Mycobacterium tuberculosis* ESAT-6 and KatG Peptides in Systemic Sarcoidosis[∇]

Wonder P. Drake,^{1*} Mary S. Dhason,² Michele Nadaf,¹ Bryan E. Shepherd,³ Sangeetha Vadivelu,¹ Rana Hajizadeh,¹ Lee S. Newman,^{4,5} and Spyros A. Kalams^{1,6}

Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee¹; Department of Biology, Texas A&M University, College Station, Texas²; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee³; Department of Preventive Medicine and Biometrics⁴ and Department of Medicine,⁵ University of Colorado at Denver and Health Sciences Center, Denver, Colorado; and Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee⁶

Received 5 May 2006/Returned for modification 6 July 2006/Accepted 20 October 2006

Sarcoidosis is an enigmatic disease with a pathology similar to that of tuberculosis. We detected Th-1 immune responses to *Mycobacterium tuberculosis* ESAT-6 and KatG peptides from peripheral blood mononuclear cells from 15/26 sarcoidosis, 1/24 purified-protein-derivative-negative (PPD−) ($P < 0.0001$, Fisher's exact test), and 7/8 PPD-positive (PPD+) subjects ($P = 0.21$). This finding provides immunologic links between mycobacteria and systemic sarcoidosis.

While the antigen(s) responsible for eliciting the sarcoidosis Th-1 immune response has not been identified (9, 13, 14), reviews of sarcoidosis immunology and pathology suggest that mycobacterial antigens could be important (6, 8). Previous studies have reported humoral responses to mycobacterial antigens among sarcoidosis subjects (4, 15) as well as the detection of mycobacterial nucleic acids and proteins in sarcoidosis granulomas (3, 5, 15). We performed enzyme-linked immunospot (ELISPOT) assays to assess for cellular recognition of two *Mycobacterium* sp. antigens (ESAT-6, an immunodominant T-cell antigen present in some members of the *Mycobacterium tuberculosis* complex but absent in *Mycobacterium bovis* BCG [2], and KatG, a catalase-peroxidase [7]) from peripheral blood mononuclear cells (PBMC) from 26 sarcoidosis, 24 purified-protein-derivative-negative (PPD−), and 11 PPD-positive (PPD+) subjects.

This study was approved by the Vanderbilt University Institutional Review Board for human studies, and informed written consent was obtained from the study participants or their surrogates. All sarcoidosis subjects from the available patient database of the Vanderbilt University Pulmonary Clinic were invited to participate in the study. For inclusion in this study, the clinical, histological, and microbiologic criteria used to define sarcoidosis were as previously described (3). Healthy PPD− volunteers were required to have undergone PPD testing by the Vanderbilt employee health services. PPD-positive subjects had written documentation of their PPD statuses and had no evidence of active disease at the time of study enrollment.

The amino acid sequences for the 17 ESAT-6 peptides, 15-mers overlapping by 10 amino acids, were as previously described (11). KatG peptides, 15-mers overlapping by 10

amino acids, were derived from the amino acid sequence of *M. tuberculosis* (GenBank accession number NP 216424) and are listed in Table 1. Each ESAT-6 and KatG peptide was synthesized by solid-phase 9-fluorenylmethoxy carbonyl (Fmoc) chemistry (Genemed Synthesis, San Diego, CA), to a purity of >70%. Identity was confirmed by mass spectroscopy and purity by high-performance liquid chromatography. PBMC were isolated from blood samples drawn into tubes containing EDTA, separated by Ficoll-Hypaque density gradient separation (Amersham Biosciences), cryopreserved in fetal calf serum with 10% dimethyl sulfoxide, and stored in liquid nitrogen until the time of the analysis.

ELISPOT assays were performed as previously described (1). The number of specific gamma interferon-secreting T cells was calculated by subtracting the mean negative-control value from the mean spot-forming-cell (SFC) count for duplicate wells inoculated with peptide. Negative controls always had <50 SFC per 10⁶ input cells. A positive response was defined as a concentration of at least 50 SFC/10⁶ PBMC that is at least

TABLE 1. Amino acid sequences for *M. tuberculosis* KatG peptides^a

Codons	Peptide sequence
91–105	WPADYGHYGPLFIRM
95–110	GHYGPLFIRMAWHAA
101–115	LFIRMAWHAAAGTYRI
106–120	AWHAAGTYRIHDGRG
111–125	GTYRIHDGRGGAGGG
116–130	HDGRGGAGGGMQRFA
121–135	GAGGGMQRFAPLNSW
126–140	MQRFAPLNSWPDNAS
301–315	KSSYGTGTGKDAITS
306–320	TGTGKDAITSGIEVV
311–325	DAITSGIEVVWTNTP
316–330	GIEVVWTNTPTKWDN
321–335	WTNTPTKWDNSFLEI
326–340	TKWDNSFLEILYGYE
331–345	SFLEILYGYEWELTK

^a GenBank accession number NP 216424.

* Corresponding author. Mailing address: Vanderbilt University School of Medicine, Division of Infectious Diseases, 1161 21st Avenue, AA2200 MCN, Nashville, TN 37232. Phone: (615) 322-2035. Fax: (615) 343-6160. E-mail: Wonder.drake@vanderbilt.edu.

[∇] Published ahead of print on 6 November 2006.

TABLE 2. Clinical and demographic characterization of study participants^a

Subject	Age, race, and sex	Disease site(s)	Immunosuppression group(s)	No. of cells ^b for indicated protein	
				KatG	ESAT-6
Sarcoidosis 1	58, AA, F	C, P	Steroids	580	100
Sarcoidosis 2	53, AA, M	P	Pentoxifylline	480	320
Sarcoidosis 3	50, C, M	P	None	300	550
Sarcoidosis 4	55, C, F	P	Steroids	300	280
Sarcoidosis 5	52, AA, F	P	None	110	500
Sarcoidosis 6	50, AA, M	P	None	90	130
Sarcoidosis 7	58, AA, M	P	Steroids	510	<50
Sarcoidosis 8	52, AA, F	P	Steroids, pentoxifylline	500	<50
Sarcoidosis 9	40, C, M	P	None	<50	590
Sarcoidosis 10	33, C, F	P	None	420	<50
Sarcoidosis 11	51, C, F	P	Steroids	370	<50
Sarcoidosis 12	31, AA, M	C, P, CNS	Steroids	240	<50
Sarcoidosis 13	33, C, F	P	None	<50	100
Sarcoidosis 14	46, AA, M	P	HIV+	120	<50
Sarcoidosis 15	62, C, M	P	None	110	<50
Sarcoidosis 16	47, C, F	P, CNS	Steroids	<50	<50
Sarcoidosis 17	51, AA, F	C	Steroids	<50	<50
Sarcoidosis 18	42, AA, F	P	Steroids	<50	<50
Sarcoidosis 19	49, AA, F	C, P	Steroids	<50	<50
Sarcoidosis 20	22, C, M	P	Steroids	<50	<50
Sarcoidosis 21	41, C, F	C, P	None	<50	<50
Sarcoidosis 22	47, AA, M	P	None	<50	<50
Sarcoidosis 23	47, C, F	P	Steroids	<50	<50
Sarcoidosis 24	51, C, F	P	None	<50	<50
Sarcoidosis 25	37, C, M	P	None	<50	<50
Sarcoidosis 26	61, C, F	P	Pentoxifylline	<50	<50
Control 1	36, AA, F	None	None	<50	380
Control 2	37, C, M	None	None	<50	<50
Control 3	23, C, M	None	None	<50	<50
Control 4	58, C, F	None	None	<50	<50
Control 5	25, C, F	None	None	<50	<50
Control 6	30, C, M	None	None	<50	<50
Control 7	27, AA, M	None	None	<50	<50
Control 8	33, C, F	None	None	<50	<50
Control 9	31, C, M	None	None	<50	<50
Control 10	31, C, F	None	None	<50	<50
Control 11	25, H, M	None	None	<50	<50
Control 12	32, C, M	None	None	<50	<50
Control 13	24, C, F	None	None	<50	<50
Control 14	37, C, F	None	None	<50	<50
Control 15	27, AA, F	None	None	<50	<50
Control 16	33, AA, F	None	None	<50	<50
Control 17	33, C, F	None	None	<50	<50
Control 18	31, AA, M	None	None	<50	<50
Control 19	51, C, F	None	None	<50	<50
Control 20	35, C, F	None	None	<50	<50
Control 21	34, AA, F	None	None	<50	<50
Control 22	34, C, M	None	None	<50	<50
Control 23	37, AA, F	None	None	<50	<50
Control 24	32, AA, F	None	None	<50	<50
PPD+ 1	45, C, F	None	None	400	500
PPD+ 2	41, AA, F	None	None	750	230
PPD+ 3	34, C, F	None	None	430	400
PPD+ 4	57, AA, M	None	None	60	500
PPD+ 5	49, C, F	None	None	280	<50
PPD+ 6	63, C, F	None	None	180	<50
PPD+ 7	64, C, F	None	None	80	<50
PPD+ 8	49, C, F	None	None	<50	<50
BCG 1	41, A, M	None	None	<50	<50
BCG 2	33, I, M	None	None	<50	<50
BCG 3	42, I, F	None	None	<50	<50

^a Ages are in years. AA, African American; A, African; C, Caucasian; H, Hispanic; I, Asian Indian; F, female; M, male; C, cutaneous; P, pulmonary; CNS, central nervous system; HIV, human immunodeficiency virus.

^b Number of gamma interferon-producing spot-forming cells per million PBMC.




FIG. 1. Distribution of T-cell frequencies for PPD- control, PPD+, and sarcoidosis subjects for KatG peptide 13. The bars represent the 25th percentile, median (50th percentile), and 75th percentile for each group; for PPD- controls, these three quantities are all equal to zero. The PPD+ group included the greatest percentage of study participants recognizing KatG peptide 13 as well as the highest median T-cell frequency. Although the sarcoidosis subjects are PPD- and have no culture evidence of infection by mycobacteria, the distribution of the T-cell frequencies for the sarcoidosis subjects was significantly different from that for the PPD- controls ($P < 0.0001$) and was closer to that for the PPD+ subjects ($P = 0.17$).




FIG. 2. Distribution of T-cell frequencies for the PPD- control, PPD+, and sarcoidosis subjects for ESAT-6 peptide 14. The bars represent the 25th percentile, median (50th percentile), and 75th percentile for each group; for PPD- controls, these three quantities are all equal to zero; for sarcoidosis subjects, the 25th percentiles and medians are both equal to zero. Although all of the sarcoidosis subjects tested were PPD-, there was a significant difference in the distribution of the T-cell frequencies for the sarcoidosis and PPD- subjects ($P = 0.024$). The lone PPD- subject who recognized ESAT-6 peptide 14 had a T-cell frequency comparable to those for the sarcoidosis and PPD+ subjects. Comparison of the sarcoidosis and PPD+ subjects revealed that there was no significant difference in the distributions of the T-cell frequencies for ESAT-6 peptide 14 ($P = 0.27$).

three times higher than the background level. The research assistants were blind to the clinical diagnoses of the study participants throughout the analysis. Comparisons of distributions of T-cell frequencies were performed using the Kruskal-Wallis test. Categorical comparisons were analyzed using Fisher's exact test. All P values are two sided and were determined using R (version 2.1.1).

Sixty-one subjects were recruited for participation in the study. Of the 26 sarcoidosis subjects, 46% were African American, 42% were male, and 58% were 50 years of age or younger. Of the 24 PPD- patients, 33% were African American, 4% were Hispanic, 38% were male, and 88% were 50 years of age or younger (Table 2). Of the 11 PPD+ subjects (8 subjects with latent tuberculosis and 3 BCG vaccinees), 18% were African American, 9% Haitian, 18% Asian Indian, 27% male, and 72% 50 years of age or younger (Table 2).

Among the 15 KatG peptides used in the ELISPOT assay, 13 of the 26 sarcoidosis subjects recognized KatG peptide 13 (codons 321 to 335) (Table 2). None of the 24 PPD- or the 3 BCG-vaccinated subjects recognized any of the 15 peptides (Table 2). Seven of the eight subjects with latent tuberculosis infection (Table 2, PPD+ 1 to 8) recognized KatG peptides 13 and 14 (codons 326 to 340). The immune recognition of KatG peptide 13 by 13 of 26 sarcoidosis subjects compared to that by 0 of 24 PPD- control subjects was statistically significant ($P < 0.0001$) (Table 2). There was no significant difference between the results for sarcoidosis subjects and subjects with latent tuberculosis. We also compared the frequencies of KatG peptide 13-specific T cells in each group. Consistent with the above-described analysis, the T-cell frequencies for

sarcoidosis subjects were higher than those for PPD- subjects ($P < 0.0001$) and lower than those for PPD+ subjects, though the latter difference was not statistically significant ($P = 0.17$) (Fig. 1).

Of the 17 ESAT-6 peptides tested, there was recognition of ESAT-6 peptide 14 (NNALQNLARTISEAG) only. Eight of 26 sarcoidosis subjects, 1 of 24 control subjects ($P = 0.024$), and 4 of 8 PPD+ subjects ($P = 0.41$) (Table 2) recognized ESAT-6 peptide 14. While two of the sarcoidosis subjects recognized ESAT-6 peptide 14 only (Table 2, sarcoidosis 9 and 13), six sarcoidosis subjects displayed immune recognition of both ESAT-6 peptide 14 and KatG peptide 13 (Table 2, sarcoidosis 1 to 6). Only one control subject recognized ESAT-6 peptide 14 (Table 2, control 1); the magnitude of this response was similar to that observed in the sarcoidosis and PPD+ participants (Fig. 2). The four PPD+ subjects who recognized ESAT-6 peptide 14 also recognized KatG peptide 13 (Table 2, PPD+ 1 to 4). There was no significant difference in the T-cell frequencies for ESAT-6 peptide 14 between the sarcoidosis and PPD+ subjects ($P = 0.27$) (Fig. 2). The three subjects with BCG vaccination recognized none of the KatG or ESAT-6 peptides. All study participants exhibited strong responses to phytohemagglutinin. Overall, 15 of 26 (58%) sarcoidosis subjects recognized KatG peptide 13 or ESAT-6 peptide 14, compared to 1 of 24 (4%) PPD- subjects ($P < 0.0001$) and 7 of 8 PPD+ subjects ($P = 0.21$).

This study suggests for the first time that despite the negative culture and histology of sarcoidosis specimens, mycobac-

terial antigens induce T-cell-specific responses in the blood of sarcoidosis patients at frequencies and magnitudes of response comparable to those for patients who are PPD+. The T-cell frequencies observed in this study are consistent with prior reports of immune recognition of mycobacterial antigens by tuberculosis subjects (Table 2) (10–12). The observation of a cellular immune response to *Mycobacterium* KatG antigens in 57% of sarcoidosis subjects closely parallels the results for prior PCR analysis (3) as well as the degree of an adaptive immune response to *M. tuberculosis* KatG proteins among sarcoidosis subjects previously reported in an independent study (15). We did not assess for immune reactivity to the entire KatG protein sequence, so it is possible that other immunogenic peptides exist. The detection of immune recognition of ESAT-6 peptide 14 and KatG peptide 13 is unlikely to be secondary to that of nonspecific reactivity or exposure to routine environmental mycobacteria. First, no significant reactivity was observed among the PPD– control subjects, who live in the same region as the sarcoidosis and PPD+ subjects. Second, ESAT-6 peptide 14 contains the amino acid sequence NNAL QNLARTISEAG, which has been previously reported to induce a CD8+ T-cell response from tuberculosis patients (10). The absence of immune reactivity to ESAT-6 peptides by BCG-vaccinated subjects served as a good internal control for the specificity of the ELISPOT assay. *M. bovis* BCG does not contain *esat-6* in its genome; thus, one would not expect to see immune reactivity to 15 ESAT-6 proteins among persons who had undergone BCG vaccination. These results support the hypothesis that mycobacterial antigens may have a role in sarcoidosis pathogenesis by demonstrating that they induce T-cell-antigen-specific Th-1 responses that are known to be important in sarcoidosis granuloma formation. This association does not imply causality but does provide another link between sarcoidosis and mycobacteria, supporting further investigation of the role of mycobacteria in sarcoidosis immunopathogenesis.

We thank Wilfred Ajayi and the Vanderbilt Pediatric Immunology Core for technical assistance with this project. We thank Ron du Bois for reviewing the manuscript.

This work was supported by grants from the National Institutes of Health (HL R21077460-01, R01 HL83839-01, and 5M01 RR 00095) and the Robert Wood Johnson Foundation (041300).

Editor: J. L. Flynn

REFERENCES

1. **Altfeld M. A., B. Livingston, and N. Reshamwala.** 2001. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. *J. Virol.* **75**:1301–1311.
2. **Behr, M. A., M. A. Wilson, W. P. Gill, H. Salamon, G. K. Schoolnik, S. Rane, and P. M. Small.** 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. *Science* **284**:1520.
3. **Drake, W. P., Z. Pei, R. D. Collins, D. Pride, T. L. Cover, and M. J. Blaser.** 2002. Molecular analysis of sarcoidosis specimens for *Mycobacterium* nucleic acids. *Emerg. Infect. Dis.* **8**:1334–1341.
4. **Dubaniewicz, A., S. Kampfer, and M. Singh.** 2006. Serum anti-mycobacterial heat shock proteins antibodies in sarcoidosis and tuberculosis. *Tuberculosis* **86**:60–67.
5. **Dubaniewicz, A., M. Dubaniewicz-Wybieralska, A. Sternau, Z. Zwolska, E. Izycka-Swieszewska, E. Augustynowicz-Kopec, J. Skokowski, M. Singh, and L. Zimnoch.** 2006. Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. *J. Clin. Microbiol.* **44**:3448–3451.
6. **Foley, N., C. Lambert, M. McNicol, N. Johnson, and G. A. Rook.** 1990. An inhibitor of tumour necrosis factor in the serum of subjects with sarcoidosis, tuberculosis and Crohn's disease. *Clin. Exp. Immunol.* **80**:395–399.
7. **Heym, B., Y. Zhang, S. Poulet, D. Young, and S. T. Cole.** 1993. Characterization of the *katG* gene encoding a catalase-peroxidase required for the isoniazid susceptibility of *Mycobacterium tuberculosis*. *J. Bacteriol.* **175**:4255–4259.
8. **Mitchell D. N., J. G. Scadding, B. E. Heard, and K. F. Hinson.** 1977. Sarcoidosis: histopathological definition and clinical diagnosis. *J. Clin. Pathol.* **30**:395–408.
9. **Newman L. S., C. S. Rose, and L. A. Maier.** 1997. Sarcoidosis. *N. Engl. J. Med.* **336**:1224–1234.
10. **Pathan, A. A., K. A. Wilkinson, R. J. Wilkinson, M. Latif, H. McShane, G. Pasvol, A. V. Hill, and A. Lalvani.** 2000. High frequencies of circulating IFN-gamma-secreting CD8+ cytotoxic T cells specific for a novel MHC class I-restricted *Mycobacterium tuberculosis* epitope in *M. tuberculosis*-infected subjects without disease. *Eur. J. Immunol.* **30**:2713–2721.
11. **Pathan, A. A., K. A. Wilkinson, P. Klenerman, H. McShane, R. N. Davidson, G. Pasvol, A. V. Hill, and A. Lalvani.** 2001. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in *Mycobacterium tuberculosis*-infected individuals: associations with clinical disease state and effect of treatment. *J. Immunol.* **167**:5217–5225.
12. **Ravn, P., M. E. Munk, A. B. Andersen, B. Lundgren, J. D. Lundgren, L. N. Nielsen, A. Kok-Jensen, P. Andersen, and K. Weldingh.** 2005. Prospective evaluation of a whole-blood test using *Mycobacterium tuberculosis*-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. *Clin. Diagn. Lab. Immunol.* **12**:491–496.
13. **Robinson, B. W., T. L. McLemore, and R. G. Crystal.** 1985. Gamma interferon is spontaneously released by alveolar macrophages and lung T-lymphocytes in subjects with pulmonary Sarcoidosis. *J. Clin. Investig.* **75**:1488–1495.
14. **Saltini, C., J. R. Spurzem, J. J. Lee, P. Pinkston, and R. G. Crystal.** 1986. Spontaneous release of IL-2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+T cell subset. *J. Clin. Investig.* **77**:1962–1970.
15. **Song, Z., L. Marzilli, B. M. Greenlee, E. S. Chen, R. F. Silver, F. B. Askin, A. S. Teirstein, Y. Zhang, R. J. Cotter, and D. R. Moller.** 2005. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic Sarcoidosis. *J. Exp. Med.* **201**:755–767.